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doi:10.1016/j.ejvs.2009.03.032Abstract Objectives: To report early clinical outcomes and learning experience following the
introduction of endovenous laser ablation (EVLA) to an NHS vascular unit.
Design: Prospective observational study.
Results: Between February 2006 and January 2008, 631 consecutive patients underwent EVLA
to 704 refluxing truncal veins e 579 GSV, 119 SSV and 6 straight segments of anterior accessory
GSV. 275/631 (44%) patients had local anaesthesia (LA) plus sedation, 237 (38%) had LA only
and 119 (18%) had general anaesthesia. All were treated using the 810 nm diode laser. Adjuvant
procedures on-table included foam sclerotherapy 129/704 (18%), multiple stab avulsions 53/
704 (8%) and 3 limbs had both. Three-month follow-up with duplex examination is complete
in 635/704 limbs (90%). Complete occlusion was noted in 610 veins (96%), 14 (2.2%) were
partially occluded and 11 (1.7%) showed no occlusion. 193 (30%) of the 635 limbs seen at
follow-up required further treatment for residual varicosities using foam sclerotherapy. There
has been one non-fatal pulmonary embolus associated with EVLA and no other complications.
Conclusions: EVLA is safe and technically effective. It has a defined learning curve requiring
new operator skills which can be readily acquired.
Crown Copyright ª 2009 Published by Elsevier Ltd on behalf of European Society for Vascular
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Varicose veins (VV) affect 10e40% of the adult population in
the United Kingdom.1,2 An estimated 60,000 VV procedures
are performed each year in the UK, comprising a significant
proportion of scheduled vascular surgical workload.3,4
Currently, due to the continuing pressure on waiting times,
there remains considerable debate regarding appropriate-
ness of utilising scarce health care resources to provide the
current venous service.5 Despite this, there is goodehalf of European Society for Vascular Surgery. All rights reserved.
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uncomplicated venous disease.6,7
Endovenous laser ablation (EVLA) for VV in the lower limb
is a minimally invasive alternative to conventional surgery,
developed by Min et al.8 Published non-randomised9e13 and
randomised studies have all clearly demonstrated the
benefits to patients in the short to medium term, with
occlusion rates of the great saphenous vein (GSV) and small
saphenous vein (SSV) in excess of 90% at follow-up of
between one and nineteen months.14e18
In February 2006 our department introduced EVLA as an
alternative treatment option for patients with symptomatic
varicose veins. Funding for capital (laser) and recurring
(disposables) costs was met by our Hospital Trust as part of
core Vascular Surgical Services provided. In our proposal it
was argued that over time we would be able to release
certain resources (e.g. anaesthetic) which could be real-
located to other services within the Hospital Trust else-
where. A prospective database of consecutive EVLA
patients has been maintained. The purpose of this paper is
to report our early outcomes following EVLA and present
the issues experienced in delivering this service.
Methods
Aberdeen Royal Infirmary is a tertiary referral centre,
a university major teaching hospital with over 1000 beds.
All patients referred to the vascular unit with VV were seen
initially at an outpatient clinic. Venous duplex scanning was
performed if a clinical diagnosis of symptomatic VV (CEAP
class 2 or above) requiring treatment was established. Pre-
operative venous duplex assessment was performed in the
vascular laboratory by our vascular technologists in
the initial period while surgeons were being trained in the
technique. From May 2006 scans were increasingly per-
formed by the surgeon in the outpatient clinic, until
December 2006 when scans were exclusively carried out by
surgeons. Two portable duplex scanners were available
with a 5 MHz transducer (Micromaxx, Sonosite, Hitchin UK,
or Logiq Book, GE Healthcare, Chalfont St. Giles, UK).
Reflux was induced with a manual calf squeeze and release
and considered significant if it exceeded 1.0 s. Refluxing
GSV, SSV or anterior accessory GSV (AAGSV) were assessed
for diameter, patency and tortuosity.
Parameters for suitability for EVLAused in our unit include
the following: treatable length of at least 10 cm, diameter
equal to or greater than 4 mm and BMI <35. Very tortuous
veins throughout their length were deemed unsuitable.
Presence of thrombus or sclerosis after phlebitis, previous
sclerotherapy or surgery, at a level too great to allowpassage
of the EVLA catheter was also classed as a contraindication.
All patients were offered EVLA routinely if suitable.
Standard open surgery was performed in those not suitable
for EVLA or if patient requested surgical treatment. Patients
with more than one refluxing truncal vein suitable for EVLA
could choose to have synchronous or staged procedures.
EVLA procedure
At first, all procedures were carried out in the daycase
operating suite. Initially all procedures were performedunder general anaesthesia and subsequently there was
a gradual transition to sedation and finally tumescent saline
only. Sedation, if used, consisted of titrated remifentanyl,
midazolam or propofol administered by the anaesthetist
according to their preference. The EVLA procedure used is
standard and has been described in detail elsewhere.19
Exceptions to this are that the only local anaesthetic used
was 0.5e1.0 ml 1% lidocaine infiltrated into the skin at the
catheter insertion site in awake patients. In the first four
months (65 patients) a very low dilution of lidocaine (less
than 0.1%) was used in the tumescent fluid but after Chong’s
publication20 we changed to using 0.9% cold saline alone.
All patients were measured for a class 2 full-length
compression stocking (Juzo, Dundee, UK) with waist
suspender, to be worn for one to two weeks after treat-
ment. The procedures were performed by one of seven
different operators. Intra-operative scanning was per-
formed by the vascular technologists until April 2006 and
thereafter by the operating surgeon.
The laser (810 nm diode) was operated at either 12 W
pulsed mode or 14 W continuous mode (surgeon choice).
The aim was to deliver 70e85 J/cm energy, for 12 W the
catheter was withdrawn at a rate of 1.4e1.7 mm/s, for
14 W the rate was 1.6e2 mm/s.
During this study period there was no specific policy
regarding adjuvant therapy. The operator made the deci-
sion whether to include phlebectomies or foam scle-
rotherapy on-table at the initial treatment or to defer
adjuvant treatment to follow-up. In general, if varicosities
were very extensive and cannulation had to be made more
than a short distance above the site where the tributary
branched off the truncal vein, foam and/or phlebectomies
were carried out at the time of EVLA.
Patients were encouraged to ambulate as soon as
possible after the procedure and were discharged one hour
after local anaesthesia or after recovery from sedation or
general anaesthesia the same day. A combination of simple
analgesia and non-steroidal anti-inflammatory drugs was
prescribed prior to discharge for four days. Written after-
care was provided and all patients offered review at three
months.
At three-month follow-up all patients were assessed by
duplex examination. Criteria for successful ablation of the
index truncal vein were non-compressibility, absence of
colour flow or absence of visible vein. Partial occlusion was
defined as visible flow of blood on duplex within a narrowed
or sclerotic channel, or ablation of a length of vein less than
the length treated with EVLA. Patients with residual vari-
cosities after confirmation of truncal closure received foam
sclerotherapy at the discretion of the surgeon or patient’s
preference.
All procedures and patient demographics were recorded
on a datasheet and entered into a prospectively maintained
database. Outcome data at scheduled follow-up have been
generated based on clinical review, duplex ultrasound
examination and the need for additional intervention.Results
Between February 2006 and January 2008, 640 consecutive
patients were admitted for planned EVLA treatment to 713
Table 1 Frequency of intervention for residual varicose
tributaries at three-month follow-up based on original index
procedure(s)
Additional procedures at 3 months nZ 635
EVLA alone
nZ 467
EVLA &
foam
nZ 124
EVLA &
avulsions
nZ 41
EVLA, foam
& avulsions
nZ 3
Initial vein treated
GSV 384 107 31 3
SSV 79 15 10 0
AAGSV 4 2 0 0
Total 467 124 41 3
Adjuvant foam therapy at 3 months n (%)
GSV 130 (34%) 32 (30%) 4 (12.9%) 0
SSV 112 (27%) 5 (33%) 0 e
AAGSV 1 (25%) 0 e e
Total 152 (33%) 37 (30%) 4 (9.8%) 0
GSVZ great saphenous vein, SSVZ small saphenous vein,
AAGSVZ anterior accessory GSV.
210 R.K. MacKenzie et al.refluxing truncal veins. There were 216 men and 424
women with a median age of 51 years (IQR 39e61). By
comparison, at the end of this period only 78/718 (11%) of
all our symptomatic VV patients underwent traditional
open surgery due to patient’s choice or unsuitability for
EVLA.
This analysis includes four failures of percutaneous
cannulation of the GSV in patients with 4 mm diameter
veins, two of whom had open surgery on that day and
a third re-attended and had successful EVLA. All four
occurred in the first seven months of us starting the tech-
nique, the last being case number 127/713. Open cannu-
lation was not attempted. A further five failures occurred
due to failure to advance the catheter along the vein due to
scarring from previous stab avulsions (2), sclerotherapy (1)
or phlebitis (2). Overall our rate of failure to gain percu-
taneous access was 4/713 (0.6%) and failure to advance the
catheter proximally was 5/713 (0.7%).
631 patients therefore underwent EVLA to 704 suitable
veins. Of these, there were 579 GSV, 119 SSV and 6 straight
segments of AAGSV at least 10 cm in length. 563 patients
had a single vein treated with EVLA, 63 had two veins
treated and five patients had three veins treated at the
same sitting. 275/631 (44%) patients had local anaesthesia
(LA) plus sedation, 237 (38%) had LA only and 119 (18%) had
general anaesthesia. The first 39 patients had general
anaesthesia. From May 2006 (case 40) we started to intro-
duce LA with sedation in increasing numbers and from June
2006 (case 65) LA with no sedation. General anaesthesia
became uncommon after this date.
491 veins were treated with 12 W in pulsed mode, 184
with 14 W in continuous mode and the rest had a mixture of
12 and 14 W in pulsed and continuous mode, according to
surgeon’s preference.
181 additional procedures performed on-table at
completion of EVLA to varicose tributaries were: foam
sclerotherapy 129/704 (18%), phlebectomies 53/704 (8%)
and 3 limbs had both. To date, three-month follow-up data
are complete in 569/631 (90%) patients with 635/704 (90%)
laser treated veins. Complete occlusion was noted in 610
(96.1%) of the treated veins on duplex scanning. Fourteen
(2.2%) were partially occluded and eleven (1.7%) had no
evidence of occlusion. 193(30%) of the 635 limbs seen at
follow-up required further treatment for residual varicosi-
ties using foam sclerotherapy (Table 1).
Over time the length of vein treated, volume of tumes-
cent saline injected, operation length and technical
outcome are summarised in Table 2 & Fig. 1. The length of
GSV treated changed little but SSV length increased. The
volume of tumescence used increased and length of oper-
ation decreased over time. Operative details regarding the
partial and no occlusions are summarised in Table 3. Anal-
ysis of gender, body mass index, operating surgeon and age
of patient showed similar numbers in the failure groups
compared to those with full occlusion. The only difference
seen was in the group with no occlusion where the energy
delivered was less than in the other two groups.
To date there has been one major complication of EVLA.
A 54-year-old female with a body mass index of 34.5
underwent bilateral GSV EVLA with bilateral phlebectomies
under general anaesthetic. Cannulation on the second limb
was difficult and the procedure lasted 90 minutes. On thefifth post-operative day she was admitted to the medical
department with a pulmonary embolism and required
anticoagulation with heparin and warfarin. Review at eight
months showed complete occlusion of the GSV with patent
deep veins and no residual varicosities. There have been no
other major complications of EVLA in our cohort, in
particular, no skin burns, pain persisting beyond three
weeks, or thermal nerve injury.
Discussion
EVLA is a safe intervention and in the short term an
effective technique for the treatment of incompetence of
the GSV, SSV and AAGSV. It has a recognisable safe learning
curve but raises several challenging issues.
There is no evidence to our knowledge that surgery for
symptomatic but uncomplicated varicose veins in young
patients who are expected to mobilise rapidly confers
a significant risk of post-operative thromboembolism. It
remains our routine practice not to administer prophylaxis
against thromboembolism during endovenous surgery. We
accept general anaesthesia, body mass index> 30 kg/m2
and operative time greater than 30 min are considered
adverse risk factors.21 It may be prudent to review one’s
own practice and consider the issue of prophylaxis when
embarking on a new intervention for operating times at
least initially may be longer.
It is appreciated that whilst we as clinicians steadily
developed the technical skills and progressed along the
learning curve in performing EVLA a significant ‘‘comfort
zone’’ was provided by GA. The specific skills to be learned
included targeted operative duplex scanning, wire/catheter
handling and accurate placement of adequate volumes of
tumescent fluid. Of these elements duplex scanning was
least familiar to the operating surgeons. Initially staff from
our Vascular Laboratory provided active duplex scanning
support, followed by perioperative training and subsequently
pre- and post-operative training in the outpatient setting. It
Figure 1 Type of anaesthetic provided over time.
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Introducing EVLA to a Vascular Surgical Unit 211was at this point that morphological features of the index
truncal vein began to be appreciated in terms of case
selection. In addition funds for portable scanning equipment
were required.
The EVLA protocol evolved as our experience with the
technique increased. We moved towards single vein
procedures as the number of GA and LA with sedation cases
reduced. This has also been the case with multiple stab
avulsions.
From the data presented a departmental experience of
approximately 200 procedures was required to achieve
satisfactory technical competency. Interestingly after the
first 200 procedures despite the operating time remaining
constant there was a trend to treat longer lengths (partic-
ularly for the SSV), using more tumescent fluid with fewer
failures at follow-up (eight in the first 200 versus one in the
next 300). It is of interest to consider whether the same
high closure rates would have been achieved had the
service commenced without anaesthetic assistance. During
this period although participating surgeons attended EVLA
workshops no surgeon attended a formal Vascular Ultra-
sound course. As more vascular ultrasound courses become
available the number of cases/duration required to achieve
competency may change.
Historically, following open superficial venous surgery
our patients were either routinely reviewed post-opera-
tively in nurse-led general vascular clinics or sent postal
questionnaires and reviewed if necessary. Currently all
EVLA patients are provided with clinical review by
a surgeon capable of venous duplex scanning and inter-
pretation of post-EVLA changes. Predictably, this has led to
increase overall outpatient activity in specific follow-up
clinics. Interestingly, 30% of our treated limbs receiving
EVLA alone or in combination with adjuvant therapy
required further treatment for residual varicosities three
months post-operatively. Ideally the most efficient scenario
would allow the operator to positively identify and predict
the need for adjuvant treatment during the initial proce-
dure. We consider that the need for adjuvant treatment
will further decrease as the absolute length of incompetent
refluxing truncal vein treated by EVLA increases as reported
originally by our colleagues from Leeds.15 Despite there
being no routine policy regarding access point we note and
Table 3 Operative details of failures
Duplex result at three months nZ 635
No occlusion Partial
occlusion
Full occlusion
Number of veins 11 (1.7%) 14 (2.2%) 610 (96.1%)
Median age
(IQR) years
58 (50e68) 55 (50e63) 52 (40e63)
No. of veins treated
GSV 10 11 504
SSV 1 3 100
AAGSV 0 0 6
Length treated in cm median (IQR)
GSV 33 (20e37) 31 (24e36) 31 (24e38)
SSV 15 10, 20, 20 18 (13e23)
AAGSV e e 16 (14e17)
Energy density J/cm median (IQR)
GSV 72 (66e83) 81 (76e84) 82 (73e86)
SSV 67 84, 85, 89 82 (72e86)
GSVZ great saphenous vein, SSVZ small saphenous vein,
AAGSVZ anterior accessory GSV.
212 R.K. MacKenzie et al.accept that the mean treated length of GSV has changed
little in this series although the range of lengths has
increased slightly. It is debateable whether patients with
confirmed occlusion of the truncal vein and only residual
branch varicosities do in fact need further therapy.
In conclusion, EVLA is a new technology which is effica-
cious and can safely be introduced into a vascular surgical
service. It has a learning curve requiring new operator skills
that can be readily acquired safely. Although EVLA can
release certain resources it may also require at least
initially, input of additional resource and training. Further
investigation is required to identify those patients best
served with additional intervention at the time of EVLA. It is
likely that with increasing experience and the development
of procedure specific packs this procedure could be deliv-
ered in an outpatient room with appropriate laser safety
precautions. Its effectiveness alongside other non-invasive/
surgical venous techniques (in terms of cost-effectiveness)
require investigation by multi-centre studies.
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